CY1116719T1 - Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου - Google Patents

Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου

Info

Publication number
CY1116719T1
CY1116719T1 CY20151100826T CY151100826T CY1116719T1 CY 1116719 T1 CY1116719 T1 CY 1116719T1 CY 20151100826 T CY20151100826 T CY 20151100826T CY 151100826 T CY151100826 T CY 151100826T CY 1116719 T1 CY1116719 T1 CY 1116719T1
Authority
CY
Cyprus
Prior art keywords
medicine
testing methods
methods
antibodies testing
relates
Prior art date
Application number
CY20151100826T
Other languages
English (en)
Inventor
Ermis Parussini
Guillaume Noguier
Original Assignee
Theradiag Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theradiag Sa filed Critical Theradiag Sa
Publication of CY1116719T1 publication Critical patent/CY1116719T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/05—Investigating sedimentation of particle suspensions in blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Dispersion Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μεθόδους ανίχνευσης αντισωμάτων αντι-φαρμάκου. Η παρούσα εφεύρεση σχετίζεται επίσης με μεθόδους παρακολούθησης ασθενών που υποβάλλονται σε αγωγή θεραπευτικού αντισώματος. Η εφεύρεση σχετίζεται επιπλέον με κιτ κατάλληλα για την εφαρμογή των ανωτέρω μεθόδων.
CY20151100826T 2010-04-29 2015-09-22 Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου CY1116719T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32920110P 2010-04-29 2010-04-29
EP10305455 2010-04-29
EP11716417.8A EP2564202B1 (en) 2010-04-29 2011-04-28 Methods for detecting anti-drug antibodies
PCT/EP2011/056732 WO2011135024A1 (en) 2010-04-29 2011-04-28 Methods for detecting antibodies

Publications (1)

Publication Number Publication Date
CY1116719T1 true CY1116719T1 (el) 2017-03-15

Family

ID=42246049

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100826T CY1116719T1 (el) 2010-04-29 2015-09-22 Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου

Country Status (19)

Country Link
US (2) US9063151B2 (el)
EP (1) EP2564202B1 (el)
JP (1) JP2013527444A (el)
KR (1) KR20130100908A (el)
CN (1) CN102884433A (el)
AU (1) AU2011247610A1 (el)
CA (1) CA2795549A1 (el)
CY (1) CY1116719T1 (el)
DK (1) DK2564202T3 (el)
ES (1) ES2548533T3 (el)
HR (1) HRP20151023T1 (el)
HU (1) HUE027662T2 (el)
IL (1) IL222533A0 (el)
PL (1) PL2564202T3 (el)
PT (1) PT2564202E (el)
RS (1) RS54249B1 (el)
SI (1) SI2564202T1 (el)
SM (1) SMT201500233B (el)
WO (1) WO2011135024A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795549A1 (en) * 2010-04-29 2011-11-03 Theradiag Sa Methods for detecting antibodies
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
MX2016005686A (es) 2013-10-31 2016-08-11 Regeneron Pharma Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
EP3084439B1 (en) * 2013-12-20 2018-09-19 Phadia AB Analysis of antibodies
US9778817B2 (en) 2013-12-31 2017-10-03 Findo, Inc. Tagging of images based on social network tags or comments
WO2015166461A1 (en) * 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
EP2982987A1 (en) 2014-08-08 2016-02-10 Proteomika, S.L. Lateral flow immunoassays for the detection of antibodies against biological drugs
MX2017005156A (es) * 2014-11-05 2017-08-08 Hoffmann La Roche Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida.
CN105277682A (zh) * 2015-11-17 2016-01-27 苏州浩欧博生物医药有限公司 一种抗TNF-α单抗药物抗体检测试剂盒
CN106093413A (zh) * 2016-07-18 2016-11-09 本·沙朗 一种抗英夫利西抗体elisa检测试剂盒和检测方法
KR20180052277A (ko) * 2016-11-10 2018-05-18 가톨릭대학교 산학협력단 항-제9응고인자 항체의 검출 방법 및 검출 키트
CN108535490A (zh) * 2017-03-06 2018-09-14 苏州和锐生物科技有限公司 生物制剂血药浓度检测方法及试剂
WO2019012531A1 (en) * 2017-07-10 2019-01-17 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODY RATES IN BIOLOGICAL DRUG SUBJECTS AND USES THEREOF IN A CUSTOMIZED MEDICINE
WO2020263450A1 (en) * 2019-06-25 2020-12-30 Procisedx Inc. Detection of anti-tnf alpha drug biologics and anti-drug antibodies
WO2023204378A1 (ko) * 2022-04-19 2023-10-26 의료법인 성광의료재단 혈액 내 항-약물항체 농도 측정을 통한 생물학적 약물에 대한 치료 반응성 예측 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520779A1 (en) 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. Agent for intra-airway administration
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
ZA200600798B (en) * 2003-07-29 2007-06-27 Genentech Inc Assay for human anti CD20 antibodies and uses therefor
BRPI0708677A2 (pt) * 2006-03-09 2011-06-21 Hoffmann La Roche ensaio de anticorpo antifármaco
CN101506659B (zh) * 2006-09-12 2012-12-12 弗·哈夫曼-拉罗切有限公司 抗药物抗体测定法
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
AU2008247352A1 (en) 2007-05-07 2008-11-13 Wyeth Elimination of interference in immunoassays caused by anti-carbohydrate antibodies
US8227195B2 (en) * 2007-12-15 2012-07-24 Hoffman-La Roche Inc. Distinguishing assay
CA2712021A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Methods and kits for detecting antibodies against therapeutic antibodies
US20110059445A1 (en) * 2008-03-28 2011-03-10 Paul Rutgeerts Mucosal gene signatures
WO2010042031A1 (en) * 2008-10-07 2010-04-15 Gyros Patent Ab Semi-sequential assay for detection of an analyte in a sample
CA2795549A1 (en) * 2010-04-29 2011-11-03 Theradiag Sa Methods for detecting antibodies

Also Published As

Publication number Publication date
CA2795549A1 (en) 2011-11-03
SMT201500233B (it) 2016-01-08
IL222533A0 (en) 2012-12-31
EP2564202B1 (en) 2015-07-01
CN102884433A (zh) 2013-01-16
WO2011135024A1 (en) 2011-11-03
HRP20151023T1 (hr) 2015-11-06
ES2548533T3 (es) 2015-10-19
JP2013527444A (ja) 2013-06-27
DK2564202T3 (en) 2015-10-05
AU2011247610A1 (en) 2012-12-13
PL2564202T3 (pl) 2016-04-29
US20130108631A1 (en) 2013-05-02
RS54249B1 (en) 2016-02-29
SI2564202T1 (sl) 2015-12-31
US9063151B2 (en) 2015-06-23
PT2564202E (pt) 2015-10-20
US9651560B2 (en) 2017-05-16
US20150285815A1 (en) 2015-10-08
EP2564202A1 (en) 2013-03-06
KR20130100908A (ko) 2013-09-12
HUE027662T2 (en) 2016-10-28

Similar Documents

Publication Publication Date Title
CY1116719T1 (el) Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου
CY1122907T1 (el) Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1124428T1 (el) Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
CY1119255T1 (el) Μεθοδος, σωληναριο και συσκευη για την παρασκευη συνθεσης επουλωσης πληγης
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
TR201904638T4 (tr) pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
UY34343A (es) Proteinas de unión al antígeno cd27l
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
CY1123172T1 (el) Δοκιμασια για συλληψη και ανιχνευση κυκλοφορουντων κυτταρων πολλαπλου μυελωματος απο αιμα
MA38632B1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
CY1118530T1 (el) Glyx-13 για χρηση σε μεθοδο θεραπευτικης αγωγης ανθεκτικης σε θεραπεια καταθλιψης
PH12014502399B1 (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
GB201202223D0 (en) Immunoassay for pyrrolidinophenones
GB201305223D0 (en) Reflection detection type measurement apparatus for skin autofluorescence